TY - JOUR
T1 - Sodium glucose co-transporter 2 inhibitor luseogliflozin in the management of type 2 diabetes
T2 - a drug safety evaluation
AU - Yabe, Daisuke
AU - Hamamoto, Yoshiyuki
AU - Seino, Yusuke
AU - Kuwata, Hitoshi
AU - Kurose, Takeshi
AU - Seino, Yutaka
N1 - Funding Information:
The authors receive Grants-in-Aid for Scientific Research from the Japan Society for Promotion of Science, Grants for Young Researchers from the Japan Association for Diabetes Education and Care, and Grants from the Japan Vascular Disease Research Foundation.
Funding Information:
The authors are especially grateful to Mss. R. Nishikino, N. Yamanaka, C. Ito of Japan Medical Data Centre Co., Ltd for sharing pharmacovigilance data on SGLT2 inhibitors. The authors also thank Ms. M. Yamane, Mr. H. Abe of Kansai Electric Power Hospital for their support. Editorial assistance was provided by Taisho Toyama Pharmaceutical Co., Ltd. Taisho Toyama provided advice on the review and input to drafts.
Publisher Copyright:
© 2017 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2017/10/3
Y1 - 2017/10/3
N2 - Introduction: Sodium glucose co-transporter-2 (SGLT2) inhibitors have been developed recently as a new class of anti-diabetic drug, and are becoming widely used in the management of type 2 diabetes (T2D). As these agents have a considerably different glucose-lowering mechanism from those of other anti-diabetic drugs, safe use of this drug class needs to be discussed based on data available from preapproval clinical trials as well as real-world studies. The SGLT2 inhibitor luseogliflozin was developed by Taisho Pharmaceutical Co., Ltd. and was approved as an oral anti-diabetic drug for T2D in Japan Areas covered: The overall safety and efficacy of SGLT2 inhibitor luseogliflozin are summarized on the basis of a literature review, with a focus on reported adverse drug reactions in preapproval clinical trials and a post-marketing surveillance. Expert opinion: SGLT2 inhibitor luseogliflozin is well tolerated, significantly improves hyperglycemia in preapproval clinical trials, and has a favorable safety profile in both preapproval clinical trials and post-marketing surveillance in elderly patients. While long-term safety and efficacy remain to be seen, luseogliflozin can benefit T2D patients worldwide. However, healthcare professionals must perform appropriate patient education that includes temporary withdrawal of luseogliflozin during patient a ‘sick day’ and avoidance of strict carbohydrate restriction during luseogliflozin treatment.
AB - Introduction: Sodium glucose co-transporter-2 (SGLT2) inhibitors have been developed recently as a new class of anti-diabetic drug, and are becoming widely used in the management of type 2 diabetes (T2D). As these agents have a considerably different glucose-lowering mechanism from those of other anti-diabetic drugs, safe use of this drug class needs to be discussed based on data available from preapproval clinical trials as well as real-world studies. The SGLT2 inhibitor luseogliflozin was developed by Taisho Pharmaceutical Co., Ltd. and was approved as an oral anti-diabetic drug for T2D in Japan Areas covered: The overall safety and efficacy of SGLT2 inhibitor luseogliflozin are summarized on the basis of a literature review, with a focus on reported adverse drug reactions in preapproval clinical trials and a post-marketing surveillance. Expert opinion: SGLT2 inhibitor luseogliflozin is well tolerated, significantly improves hyperglycemia in preapproval clinical trials, and has a favorable safety profile in both preapproval clinical trials and post-marketing surveillance in elderly patients. While long-term safety and efficacy remain to be seen, luseogliflozin can benefit T2D patients worldwide. However, healthcare professionals must perform appropriate patient education that includes temporary withdrawal of luseogliflozin during patient a ‘sick day’ and avoidance of strict carbohydrate restriction during luseogliflozin treatment.
UR - http://www.scopus.com/inward/record.url?scp=85027859364&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85027859364&partnerID=8YFLogxK
U2 - 10.1080/14740338.2017.1359252
DO - 10.1080/14740338.2017.1359252
M3 - Article
C2 - 28741382
AN - SCOPUS:85027859364
VL - 16
SP - 1211
EP - 1218
JO - Expert Opinion on Drug Safety
JF - Expert Opinion on Drug Safety
SN - 1474-0338
IS - 10
ER -